Published by Biocell Center 2013, April

FETAL STEM CELLS

Amniotic, Chorionic Villi and Fetal stem cells: updates from the world of research

Chicago BIO 2013

Biocell Center – world leader in fetal stem cells preservation - has 4 innovative products and related patents: Chorionic Villi stem cells at birth and during CVS, Amniotic stem cells at birth and during amniocentisis. Come and visit us at the Italian delegation booth #4217

BIO International Convention
The Global Event for Biotechnology

Hot news

Now it's possible to collect stem cells from chorionic villi at birth

Chicago, IL - Scientists certified the extraordinary qualities of chorionic villi, which are one of the best sources of fetal stem cells.

Today Biocell Center has announced it is possible to preserve in an aseptic and correct way stem cells from chorionic villi of the placenta after birth, through an international patent based on both a method and a proprietary medical device. This is an important step as it provides a new collecting and cryopreservation service available for all children, regardless the need of Chorionic Villi Sampling (CVS). In fact, it will be enough for the father to collect a little sample of placenta by using a specific and user-friendly medical device designed by Biocell Center, and problem solved! The sample will be sent to Biocell Center, processed in a sterile environment, and cryopreserved for decades in liquid nitrogen, until the occurrence of a therapeutic need.

Technical and scientific features of the service, together with the literature included in the last edition of the "Scientific Paper Review", will be presented at the BIO 2013 event held in Chicago. "Our aim is to give to everybody the possibility to benefit from his own biological heritage, represented by the fetal stem cells, hoping that they will be useful for the treatment of several human diseases" - said Professor Giuseppe Simoni, Scientific Director at Biocell Center.

The service has been now experimentally launched in Italy and US, and will be available worldwide starting from next September for a cost of about 2,000 USD, which includes 19 years of cryopreservation.

International Papers

Human amniotic fluid stem cells protect rat lungs exposed to moderate hyperoxia
Grisafi et alt.
Pediatr Pulmonol. 2013 Mar 26.

Neurorescue effects and stem properties of chorionic villi and amniotic progenitor cells.
Calzarossa et al.
Neuroscience. 2013 Mar 27

Therapeutic potential of amniotic fluid stem cells
Abdulrazzak , De Coppi, Guillot
Curr Stem Cell Res Ther. 2013 Mar

The contribution of stem cell therapy to skeletal muscle remodeling in heart failure
Castellani et al.
Int J Cardiol. 2013 Feb 28.

Amniotic and Chorionic Villi Stem Cells

SCIENTIFIC PAPER REVIEW

Seventy international publications on amniotic fluid and chorionic villi stem cells included in the April 2013 edition of the Biocell Scientific Paper Review. "What is extraordinary – says Dr. Massimiliano Manganini, director of the Biocell cryobank - is that all, absolutely all publications end up classifying fetal stem cells as a potential source for clinical applications".

Ask your free copy: info@biocellcenter.com

Stem cells contained in Amniotic Fluid

BIN - A group of companies for bone reconstruction



Milan (Italy) - One of the most innovative projects presented in Chicago BIO 2013 is Italian and comes from Lombardia: its name is BIN, which stands for Biotechnologies for Therapeutic Innovation. The aim of this project is to find out remedies for osteoarticular injuries through the production of a medical device realized by using stem cells, biomimetic scaffolds and nanovectors. The five companies involved in this project are: Biocell Center, Gexnano, Ibi-Industrie Insubri, Imaginor and Monkeytrip.

Stem cells that will be used for the project are derived from the amniotic fluid, cultivated after cryopreservation in liquid nitrogen, and then thawed to test their proliferative capacity after the cell "trauma" associated to the cryopreservation. Then, by the means of a nanovector, it will be determined the correct strategy to allow the stem cells to fully colonize a customized artificial scaffold mould into a desired shape.

The aim is to realize a device useful for the treatment of bone and cartilaginous degeneration and traumatic pathologies, defining methods, procedures and "replacement parts" as well.

Renato Colognato, researcher at Gexnano, says: "We intend to gather together the efforts of different companies in order to realize an important step towards the industrialization of a product, and to promote ourselves in the market as a single network group supported by correct informatics and communication devices".

The project – co-funded by Regione Lombardia and Ministero dell'Università e della Ricerca Scientifica through the ERGON supporting program – will end at the end of the year, and the companies involved in the project will introduce the first data in Chicago in order to obtain the collaboration of important international Institutions. This will be a showcase for Lombardia companies and a hope for the treatment of very common pathologies. *BIN is at BIO2013 at the Italian delegation booth #4217.*

BIOCELL CENTER CORP.
200 Boston Av. 02155 – Medford (MA,USA)
Ph. +1 781 391 2040 – Fax +1 781 395 0602
Toll Free 866 BIO 2720
info@biocellcenter.com/www.biocellcenter.com

BIOCELL CENTER SPA
Viale Stelvio 125, 21052 – Busto A. (Va)
Tel. 0331-386028 / Fax 0331367321
info@biocellcenter.it / www.biocellcenter.it

BIOCELL CENTER – the FIRST AMNIOTIC and CHORIONIC VILLI CRYOBANK in the WORLD – has been studying amniotic fluid stem cells for years as an "ethical" alternative to embryonic stem cells.

In the laboratories of Milan (Italy) and Medford (MA, USA) there are several researches with the goal of discovering therapies and methods for the treatment of human diseases, and there are cryobanks as well, where it is possible to preserve fetal stem cells collected through amniocentesis and villocentesis, with the hope of being able to use them in the future – if needed – on babies born today.

But neither Biocell nor anyone else can offer treatment and Biocell Center warns about being very careful about this matters: the sole stem cells clinical applications are those authorized by official authorities of health.

The purpose of this publication is updated on the progress of research in these fields and to release an appropriate and reliable scientific information.